In a small initial study of oncogene activation in differentiated thyroid cancer, using DNA transfection and tumorigenicity assays, we identified activating ras mutations in 80% (4/5) of follicular carcinomas, but in only 20% (2/10) of papillary carcinomas (Lemoine et al., 1988) . However, Suarez et al. (1988), using the 'focus' transformation assay, reported two out of a total of three papillary carcinomas to have activated ras oncogenes, while Fusco et al. (1987) , also using DNA transfection techniques, failed to find any activating ras mutations in 20 papillary cases analysed. These conflicting results indicated the need for further study of the prevalence of ras mutations in thyroid cancer.
In a small initial study of oncogene activation in differentiated thyroid cancer, using DNA transfection and tumorigenicity assays, we identified activating ras mutations in 80% (4/5) of follicular carcinomas, but in only 20% (2/10) of papillary carcinomas (Lemoine et al., 1988) . However, Suarez et al. (1988) , using the 'focus' transformation assay, reported two out of a total of three papillary carcinomas to have activated ras oncogenes, while Fusco et al. (1987) , also using DNA transfection techniques, failed to find any activating ras mutations in 20 papillary cases analysed. These conflicting results indicated the need for further study of the prevalence of ras mutations in thyroid cancer.
We now report a further series of papillary carcinomas, analysed by polymerase chain reaction (PCR) amplification and oligonucleotide probing of archival material, and summarise our data on the incidence and type of mutation in a total of 33 differentiated thyroid carcinomas.
Wax-embedded tissue blocks of eight papillary thyroid carcinomas (up to 7 years old) were obtained from the archives of the Department of Pathology, University of Wales College of Medicine. Sections of 5.m were deparaffinised twice with xylene, washed twice with ethanol and vacuum desiccated (Shibata et al., 1988) . Dried pellets were mixed with sterile water, denatured for 10 min at 95°C and rapidly cooled to 4'C. PCR incubations were prepared with a Perkin Elmer/Cetus Gene Amp kit according to the manufacturers' protocol. Final concentrations were 10 mM Tris pH 8.3, 50 mM KCI, 1.5 mM MgCl2, 0.2 mM of each dNTP, 1 tIM of each of a pair of amplimers and 2.5 units of Taq DNA polymerase (Saiki et al., 1986) . Amplimers were 20 bases long, each pair enclosing an amplified region of 100 bp. Samples received 50 cycles of amplification in a Cetus thermal cycler, with 1 min denaturation at 94°C, 2.5 min annealing at 55'C and 3 min extension at 72°C. A 10 pl aliquot of each incubation was run on a 2.5% agarose gel to check for specific amplification, and reactions were repeated until sharp single bands were obtained.
After an initial quantitation, 5-12gdl of each PCR-amplified mixture was diluted to 200 t l I in 1O mM Tris pH 8.0/ 1 mM EDTA, denatured at 95°C for 5 min and cooled rapidly to 4'C. Replicate slotblots, prepared using Hybond-N filters (Amersham) and a Millipore vacuum slotblot apparatus were prehybridised at 56°C for 30 min in 3 M tetramethylammonium chloride (TEMAC)/50 mM Tris pH 7.5/2 mM EDTA/0.3% SDS/5 x Denhardts solution, 100 flg ml-' denatured herring sperm DNA (Wood et al., 1985) . Filters were hybridised for 1-2 h at 56°C with 32P-endlabelled 20mer oligonucleotide probes specific for mutations altering aminoacids at the 12, 13, and 61 positions of each of the three human ras genes. As a check on quantitation, filters were first autoradiographed after non-stringent washes in 2 x SSPE/0.1% SDS at room temperature. They were then (Figure 1) . Case 7 showed an A-*C transversion at position 2 of codon 61 of the K-ras gene giving a glutamine+proline substitution (Figure 2 ). (For case 4, non-tumour tissue was also assayed; it did not contain the mutation).
When these results are combined with our previous series of papillary carcinomas, this gives a total of three mutations out of 17 cases tested. (One previous case, in which ionising radiation was the probable aetiological agent, has been excluded since studies in progress indicate that radiation exposure significantly influences the incidence of ras mutation in these tumours.) Since the other previously reported mutation (Lemoine et al., 1988) was K-ras 13, glycine-*aspartate, all three mutations detected in papillary cancers have been different. In contrast, the combined total for our two series of follicular cancers (Lemoine et al., 1988 (Lemoine et al., , 1989 (Final high stringency washes carried out at 62°C.)
6" The Macmillan Press Ltd., 1989 Br. J. Cancer (1989 mutations out of 15 cases tested, with four of these having the same H61 glutamine-*arginine substitution, and one having an N61 glutamine-*arginine substitution. (The remainder were H12 glycine-*aspartate, K12 glycine-*serine, and N61 glutamine-*leucine.) Several points arise from this new data. First, as far as we are aware, this is the first report of a K61 proline mutation in a human cancer. Secondly, we have now confirmed in a larger series that the overall rate of ras mutation in papillary carcinomas (3/17; 17%) is significantly lower than in follicular carcinomas (8/15; 53%), (X2= 4.95; P<0.05). Thirdly, none of the 17 papillary cases had a position 61 glutamine-*arginine substitution, compared to five out of 15 follicular cancers.
We have therefore identified a statistically significant (though not absolute) distinction in the prevalence of a specific oncogene mutation in two types of carcinoma arising from the same cell of origin, the thyroid follicular cell. It would seem likely that this difference in ras oncogene activation is related to the known differences in epidemiology, pathology and clinical behaviour of the two cancers.
One important difference lies in their metastatic potential. Follicular carcinomas disseminate widely in the bloodstream, whereas papillary carcinomas spread locally via lymphatics (Frazell & Foote, 1958) . Experimental transformation of non-tumorigenic rodent fibroblast lines with an activated Ha-ras gene has been shown to confer ability to metastasise via the bloodstream (Muschel et al., 1985) and to increase production and secretion of proteases such as cathepsin L which are likely to contribute to this process (Denhardt et al., 1987) . However, our data do not suggest that ras is an absolute and sole determinant of metastatic potential in thyroid tumour cells, since a significant minority (17%) of papillary carcinomas do have a potentially activating ras mutation.
An alternative explanation for the different pattern of ras mutation is suggested by our study of thyroid adenomas (Lemoine et al., 1989) , which showed that the prevalence of ras mutation is as high in micro-follicular adenomas as in follicular carcinomas. There is evidence that follicular carcinomas arise from pre-existing adenomas, whereas papillary carcinomas classically arise de novo (De Groot et al., 1984) . Thus the higher rate of ras mutation in follicular carcinomas may simply reflect their origin from adenomas, in which ras activation presumably plays a key early role, and may not be related directly to the differences in behaviour of the cancers.
It is not clear whether the subset of papillary cancers which do contain a mutant ras gene show any difference in biological behaviour, e.g. increased metastatic potential or a worse prognosis, compared to the majority. In our series there was no detectable correlation with any clinical or histopathological features but clearly a much larger, prospective study will be needed to establish this with certainty.
